Sweden-based Wilson Therapeutics AB has appointed Andrew Kay as chair of its board of directors to help the company develop its lead product for Wilson’s Disease, a rare autosomal recessive disorder. Mr Kay is the former chief executive of Algeta ASA, a Norwegian radiopharmaceutical company acquired by Bayer in 2014. Prior to this he was global head of marketing and sales at Novartis and before that, he held commercial positons in Europe at AstraZeneca Plc, Eli Lilly and Company, Sandoz (Novartis) and Boots.
Wilson Therapeutics announced the appointment on 20 October 2015.
Copyright 2015 Evernow Publishing Ltd